• Flanders Investment & Trade
  • Team Vesalius

Mark Vaeck has more than 30 years of experience in the biotech and pharma industry.

Mark Vaeck


Agoralaan A-bis
3590 Diepenbeek

As a serial entrepreneur he raised more than €100 million in equity financing for the biotech companies he helped creating. In 2008, he co-founded Complix and was appointed CEO in May 2010.

Prior to this, in 2006, Mark co-founded ActoGeniX (Belgium) and served as its CEO until 2010. He was also the founding CEO of Ablynx (Belgium) from 2001 until 2006. Before joining Ablynx, Mark was COO of Ceres Inc. (US), a NASDAQ listed company developing innovative technologies for biofuel production. From 1987 to 1998, he held several business development and general management positions in the biotech and pharma industry, including at UCB, Chiron, Keygene and PGS. Mark holds a PhD in Immunology from the Free University of Brussels

Team Vesalius visionairies

Flanders’ life sciences industry: the perfect combo of biotech, medtech, pharma and healthcare

Defining Flanders’ life sciences industry as diverse is an understatement. From young start-ups to established local firms and multinationals: the entire value chain – from research and discovery to development and commercialization – is represented in Belgium’s northern region. Thanks to fertile cross-pollination between biotech, medtech, pharmaceuticals and healthcare, Flanders offers a unique life sciences ecosystem that is underpinned by a robust financing landscape and a supportive government. Will your company claim its place in this dynamic hub?